The PARP inhibitors have been approved for the clinical treatment of metastatic and recurrent ovarian and breast cancer patients with BRCA1/2 mutations by FDA, and there are a number of on-going clinical trials for treating other types of cancers with PARPi 15, 16. Here, PARP1 is linked to breast cancer.